Pimpri Police Arrest Medical Shop Owner For Selling Fake Cancer Injections, Seizes Rs 3.5 Lakh Worth Drugs

Pimpri: The Pimpri police have arrested a medical shopkeeper involved in manufacturing and selling counterfeit cancer injections that were not approved for sale in India. The arrested individual has been identified as Shriprasad Shrihari Kulkarni, a 42-year-old resident of Rohan Radhika Apartment, near Prathamesh Nagri, Sun City, Sinhagad Road. Authorities have seized two boxes of fake cancer injections worth Rs 3.5 lakh from him, each of which he sold for Rs 1 lakh.

The case came to light after Mahesh Vishnu Kamble, a 42-year-old resident of Janwadi, lodged a complaint with the Pimpri police. According to the police, the injection in question, Adcetris, produced by TAKEDA Pharmaceutical Ltd. for cancer treatment, is not manufactured for sale in India. The pharmaceutical company informed Kamble that Kulkarni had been selling counterfeit versions of the drug in Pune.

Further, the plaintiff learnt that the accused was selling the drugs only to cancer patients. Therefore, to verify the allegations, a woman with cancer was asked to place an order for two injections. Kulkarni charged her Rs 2 lakh for the fake injections. The woman sent the injections to the pharmaceutical company for verification, which, after the examination, confirmed that they were counterfeit.

Accordingly, Kamble then reported the incident to Pimpri police. In a subsequent operation, the woman again placed an order for two injections. Kulkarni was apprehended when he came to deliver the fake injections at Niramay Hospital. During the search, police found two boxes of counterfeit injections valued at Rs 3.5 lakh. Assistant Police Inspector Dr. Ashok Dongre is leading the ongoing investigation into the matter.

Related Posts

  • Pharma
  • July 11, 2025
  • 80 views
India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

July:  India’s Glenmark Pharmaceuticals (GLEN.NS), opens new tab said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie (ABBV.N), opens new tab have signed an exclusive licensing agreement…

  • Pharma
  • July 10, 2025
  • 140 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

India’s Glenmark Pharma unit, AbbVie sign exclusive licensing pact

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies